Precipio (NASDAQ:PRPO) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Precipio (NASDAQ:PRPO) to a hold rating in a report published on Saturday morning.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Precipio in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Precipio Trading Up 4.3%

Precipio stock opened at $23.39 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.10 and a current ratio of 1.27. Precipio has a fifty-two week low of $3.90 and a fifty-two week high of $28.50. The stock has a market cap of $40.93 million, a P/E ratio of -28.52 and a beta of 1.20. The firm’s fifty day moving average price is $23.60 and its 200-day moving average price is $20.46.

Precipio (NASDAQ:PRPO) last posted its earnings results on Friday, November 14th. The biotechnology company reported ($0.05) EPS for the quarter. The business had revenue of $6.77 million for the quarter. Precipio had a negative return on equity of 10.07% and a negative net margin of 5.50%.

Institutional Investors Weigh In On Precipio

Hedge funds have recently made changes to their positions in the business. AMH Equity Ltd raised its position in Precipio by 370.1% in the 3rd quarter. AMH Equity Ltd now owns 131,100 shares of the biotechnology company’s stock worth $2,332,000 after purchasing an additional 103,210 shares during the period. Renaissance Technologies LLC grew its stake in shares of Precipio by 10.7% during the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock valued at $333,000 after buying an additional 1,400 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Precipio by 5.1% during the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock valued at $377,000 after buying an additional 789 shares during the last quarter. Susquehanna International Group LLP purchased a new position in shares of Precipio in the third quarter worth about $194,000. Finally, Topline Capital Management LLC bought a new stake in shares of Precipio in the 3rd quarter valued at about $1,158,000. 10.45% of the stock is currently owned by institutional investors.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.